SlideShare une entreprise Scribd logo
1  sur  2
Télécharger pour lire hors ligne
JOURNAL OF PALLIATIVE MEDICINE
Volume 13, Number 8, 2010                                                           Fast Facts and Concepts
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jpm.2010.9800




                            Evaluation of Malignant Ascites #176

                                           Karen LeBlanc and Robert M. Arnold, M.D.



Background                                                               draining lymphatics, portal vein thrombosis, elevated portal
                                                                         venous pressure from cirrhosis, congestive heart failure,

M      alignant ascites is the accumulation of abdominal
       fluid due to the direct effects of cancer. This Fast Fact
reviews the causes and diagnosis of malignant ascites. Fast
                                                                         constrictive pericarditis, nephrotic syndrome, and peritoneal
                                                                         infections.
                                                                            Depending on the clinical presentation and expected sur-
Fact #177 will review its treatment.                                     vival, a diagnostic evaluation is usually indicated, as it will
                                                                         affect both prognosis and treatment approach. Key tests in-
Pathophysiology                                                          clude the serum albumin and protein level and a simulta-
                                                                         neous diagnostic paracentesis, checking ascitic fluid white
   The pathophysiology of malignant ascites is incompletely              blood cell count, albumin, protein, and cytology.
understood. Contributing mechanisms include tumor-related
obstruction of lymphatic drainage, increased vascular perme-             Classification
ability, over-activation of the renin-angiotensin-aldosterone
system, neoplastic fluid production, and production of me-                   The old classification of exudative versus transudative as-
talloproteinases that degrade the extracellular matrix. Portal           cites has been updated using the serum-ascites albumin gra-
venous compression can also occur from metastatic invasion of            dient (SAAG).
the liver, leading to peritoneal fluid accumulation.
                                                                         SAAG = (the serum albumin concentration) – (ascitic
                                                                         fluid albumin concentration)
Natural History
                                                                            A SAAG 1.1 g/dl indicates ascites due to, at least in part,
   The most common cancers associated with ascites are ad-
                                                                         increased portal pressures, with an accuracy of 97%. This is
enocarcinomas of the ovary, breast, colon, stomach, and
                                                                         most commonly seen in patients with cirrhosis, hepatic con-
pancreas. Median survival after diagnosis of malignant ascites
                                                                         gestion, CHF, or portal vein thrombosis.
is in the range of 1–4 months; survival is apt to be longer for
                                                                            A SAAG  1.1 g/dl indicates no portal hypertension, with
ovarian and breast cancers if systemic anti-cancer treatments
                                                                         an accuracy of 97%; most commonly seen in peritoneal carci-
are available.
                                                                         nomatosis, an infectious process of the peritoneum, nephrotic
                                                                         syndrome, or malnutrition/hypoalbuminemia.
Presentation and Diagnostics                                                Cytological evaluation is approximately 97% sensitive in
   Symptoms include abdominal distension, nausea, vomit-                 cases of peritoneal carcinomatosis, but is not helpful in the
ing, early satiety, dyspnea, lower extremity edema, weight               detection of other types of malignant ascites due to massive
gain, and reduced mobility. Physical exam findings may in-                hepatic metastasis or malignant obstruction of lymph vessels.
clude abdominal distention, bulging flanks, shifting dullness,
and a fluid wave. Plain abdominal x-rays are not specific, but             References
may show a hazy or a ‘‘ground glass’’ appearance. Ultrasound             1. Thomas J, von Gunten CF: Diagnosis and management of
or CT scanning can confirm the presence of ascites and                       ascites. In Berger AM, Von Roenn J, Schuster J, eds. Principles
demonstrate if the fluid is loculated in discrete areas of the               and Practice of Palliative Care and Supportive Oncology, 3rd ed.
peritoneal cavity.                                                          Philadelphia, PA: Lippincott, Williams  Wilkins; 2006.
   There are many potential causes of ascites in the cancer              2. Adam RA, Adam YG: Malignant ascites: Past, present, and
patient: peritoneal carcinomatosis, malignant obstruction of                future. J Am Coll Surg 2004;198:999–1011.


   Fast Facts and Concepts are edited by Drew A Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For more information,
write to: drosiell@mcw.edu. More information, as well as the complete set of Fast Facts, are available at EPERC: www.eperc.mcw.edu.
   Version History: Current version re-copy-edited in May 2009.
   Copyright/Referencing Information: Users are free to download and distribute Fast Facts for educational purposes only. LeBlanc K,
Arnold RA. Evaluation of Malignant Ascites. Fast Facts and Concepts. March 2007; 176. Available at: www.eperc.mcw.edu/fastfact/
ff_176.htm.
   Disclaimer: Fast Facts and Concepts provide educational information. This information is not medical advice. Health care providers should
exercise their own independent clinical judgment. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other
than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such
product is used.

                                                                     1027
1028                                                                                               FAST FACTS AND CONCEPTS

3. Spratt JS, Edwards M, Kubota T, et al: Peritoneal carcino-                                            Address correspondence to:
   matosis: Anatomy, physiology, diagnosis, management. Curr                                                 Robert M. Arnold, M.D.
   Probl Cancer 1986;10:553–584.                                                                         Division of Internal Medicine
4. Becker G, Galandi D, Blum HE: Malignant ascites: Systematic                                                University of Pittsburgh
   review and guideline for treatment. Eur J Cancer 2006; 42:589–597.                                           200 N. Lothrop Street
5. Aslam N, Marino CR. Malignant ascites: New concepts in                                                       Pittsburgh, PA 15213
   pathophysiology, diagnosis, and management. Arch Intern
   Med 2001; 161:2733–2737.                                                                                    E-mail: rabob@pitt.edu




DOI: 10.1089/jpm.2010.9799




                Palliative Treatment of Malignant Ascites #177

                                          Karen LeBlanc and Robert M. Arnold, M.D.



Background                                                                   extended duration (peritonitis, accidental removal,
                                                                             leakage, occlusion).

T    he natural history, presenting signs/symptoms, and
     diagnostic approach to the patient with malignant
ascites are discussed in Fast Fact #176; readers are encouraged
                                                                          b. Tunneled catheter: A catheter that prevents infection by
                                                                             promoting scarring around an antibiotic-impregnated
                                                                             Dacron cuff in subcutaneous tissue. Used convention-
to read this Fast Fact to review the important role of deter-                ally for peritoneal dialysis, it is placed with ultrasound
mining the serum-ascites albumin gradient (SAAG) as a diag-                  or fluoroscopic guidance and has lower risks of infec-
nostic and treatment aid. This Fast Fact will review treatment               tion and leakage than the pigtail catheter. Complica-
approaches.                                                                  tions are reduced by daily drainage for the first 2 weeks
                                                                             of cuff healing. The Pleurx catheter is FDA approved
1. Diuretics                                                                 for malignant ascites, and features a one-way rubber
                                                                             valve to prevent leaks between draining sessions.
  Malignant ascites (SAAG  1.1) generally does not re-
                                                                             Tunneled catheters are used in patients with a life ex-
spond to diuretic treatment, although no randomized trials
                                                                             pectancy of at least 1 month.
have been completed. Patients with evidence of portal
hypertension (SAAG  1.1) are more likely to respond to
diuretics.                                                              4. Vascular Shunts

2. Paracentesis                                                           a. Peritovenous shunt (PVS) systems are designed to
                                                                             channel peritoneal fluid and proteins in benign as-
   Paracentesis can provide immediate relief of symptoms                     cites back into the circulation via the superior vena
in up to 90% of patients. Drainage of uncomplicated large-                   cava. PVS has not been shown to have clinically
volume ascites (4–6 L/session) can be done safely and quickly                significant risk of disseminating tumor cells in
in the outpatient setting—including the home—or at the                       malignant ascites. A PVS is placed by interventional
hospital bedside; ultrasound guidance is necessary only when                 radiology under conscious sedation, and patients
there is loculated fluid.                                                     typically require 24 hours of monitoring with a
                                                                             central venous line after the procedure. The best
3. Drainage catheters                                                        response to PVS (only about 50%) is in ovarian and
                                                                             breast cancers. PVS is recommended only in patients
   For patients who require frequent paracentesis, external
                                                                             with a life expectancy of 1 to 3 months.
drainage catheters placed through the abdominal wall allow
                                                                          b. Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a
frequent or continuous drainage of ascites fluid without re-
                                                                             shunt between the portal vein and hepatic vein, de-
petitive needle insertions. Patients or caretakers may perform
                                                                             signed to reduce portal hypertension and improve
the drainage, reducing visits to medical clinics. Several types
                                                                             sodium balance. Most patients with malignant ascites
of catheters are available including:
                                                                             do not have portal hypertension although TIPS might
   a. Pigtail catheter: A simple, temporary all-purpose cath-                be helpful in the occasional cancer with evidence of
      eter; prone to complications when used over an                         increased portal pressures (SAAG  1.1).

Contenu connexe

Tendances

Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomadocatuljain
 
臨床上較少見之肝臟腫瘤20130906 management
臨床上較少見之肝臟腫瘤20130906 management臨床上較少見之肝臟腫瘤20130906 management
臨床上較少見之肝臟腫瘤20130906 managementChien-Wei Su
 
臨床上較少見之肝臟腫瘤20130906
臨床上較少見之肝臟腫瘤20130906臨床上較少見之肝臟腫瘤20130906
臨床上較少見之肝臟腫瘤20130906Chien-Wei Su
 
Hepatocellular carcinoma 2020
Hepatocellular carcinoma 2020Hepatocellular carcinoma 2020
Hepatocellular carcinoma 2020AbrahamGenetu
 
Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC)Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC)Saood Malik
 
Liver cancer by Dr. Basil Tumaini
Liver cancer by Dr. Basil TumainiLiver cancer by Dr. Basil Tumaini
Liver cancer by Dr. Basil TumainiBasil Tumaini
 
Tumors of gallbladder
Tumors of gallbladderTumors of gallbladder
Tumors of gallbladderPratap Tiwari
 
Metastatic liver disease (2)
Metastatic liver disease (2)Metastatic liver disease (2)
Metastatic liver disease (2)mostafa hegazy
 
Nodular hyperplasia of the liver
Nodular hyperplasia of the liverNodular hyperplasia of the liver
Nodular hyperplasia of the liverDr./ Ihab Samy
 
Paediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaPaediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaDrArka
 
Pediatric liver masses
Pediatric liver massesPediatric liver masses
Pediatric liver massesSidra Afzal
 
carcinoma of stomach
 carcinoma of  stomach carcinoma of  stomach
carcinoma of stomachVeeru Reddy
 

Tendances (20)

Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
臨床上較少見之肝臟腫瘤20130906 management
臨床上較少見之肝臟腫瘤20130906 management臨床上較少見之肝臟腫瘤20130906 management
臨床上較少見之肝臟腫瘤20130906 management
 
臨床上較少見之肝臟腫瘤20130906
臨床上較少見之肝臟腫瘤20130906臨床上較少見之肝臟腫瘤20130906
臨床上較少見之肝臟腫瘤20130906
 
Hepatocellular carcinomas
Hepatocellular carcinomasHepatocellular carcinomas
Hepatocellular carcinomas
 
Hepatocellular carcinoma 2020
Hepatocellular carcinoma 2020Hepatocellular carcinoma 2020
Hepatocellular carcinoma 2020
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
CHOLANGIOCARCINOMA- BILE DUCT CANCER
CHOLANGIOCARCINOMA- BILE DUCT CANCERCHOLANGIOCARCINOMA- BILE DUCT CANCER
CHOLANGIOCARCINOMA- BILE DUCT CANCER
 
Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC)Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC)
 
Liver cancer by Dr. Basil Tumaini
Liver cancer by Dr. Basil TumainiLiver cancer by Dr. Basil Tumaini
Liver cancer by Dr. Basil Tumaini
 
Tumors of gallbladder
Tumors of gallbladderTumors of gallbladder
Tumors of gallbladder
 
Biliary tract cancer
Biliary tract cancerBiliary tract cancer
Biliary tract cancer
 
Metastatic liver disease (2)
Metastatic liver disease (2)Metastatic liver disease (2)
Metastatic liver disease (2)
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Nodular hyperplasia of the liver
Nodular hyperplasia of the liverNodular hyperplasia of the liver
Nodular hyperplasia of the liver
 
Paediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinomaPaediatric Hepatocellular carcinoma
Paediatric Hepatocellular carcinoma
 
Pediatric liver masses
Pediatric liver massesPediatric liver masses
Pediatric liver masses
 
HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)HCC MANGEMENT(RAD ONCO)
HCC MANGEMENT(RAD ONCO)
 
carcinoma of stomach
 carcinoma of  stomach carcinoma of  stomach
carcinoma of stomach
 
Liver cancer
Liver cancer Liver cancer
Liver cancer
 
gastric cancer
gastric cancergastric cancer
gastric cancer
 

Similaire à Evaluation of malignant ascites #176

Palliative treatment of malignant ascites #177
Palliative treatment of malignant ascites #177Palliative treatment of malignant ascites #177
Palliative treatment of malignant ascites #177Clinica de imagenes
 
Malignant ascites dr. varun
Malignant ascites dr. varunMalignant ascites dr. varun
Malignant ascites dr. varunVarun Goel
 
Premalignant conditions in Breast.pptx
Premalignant conditions in Breast.pptxPremalignant conditions in Breast.pptx
Premalignant conditions in Breast.pptxDr Kartik Kadia
 
Advances in the management of pancreatic cancer
Advances in the management of pancreatic cancerAdvances in the management of pancreatic cancer
Advances in the management of pancreatic cancerPromise Echebiri
 
Staging and investigation of hepatobillary ca
Staging and investigation of hepatobillary caStaging and investigation of hepatobillary ca
Staging and investigation of hepatobillary caAtulGupta369
 
Grish hcc presentation
Grish hcc presentationGrish hcc presentation
Grish hcc presentationsadiqsikora
 
Gastroenterology-Part A.pptx
Gastroenterology-Part A.pptxGastroenterology-Part A.pptx
Gastroenterology-Part A.pptxbesoneso
 
Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)Usama Ragab
 
Non-Alcoholic Tumor Disease
Non-Alcoholic Tumor DiseaseNon-Alcoholic Tumor Disease
Non-Alcoholic Tumor DiseaseNicole Jones
 
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...i3 Health
 
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009medbookonline
 
Colo rectal cancer management
Colo rectal cancer managementColo rectal cancer management
Colo rectal cancer managementBachar Raad
 
Acs0604 Acute Mesenteric Ischemia
Acs0604 Acute Mesenteric IschemiaAcs0604 Acute Mesenteric Ischemia
Acs0604 Acute Mesenteric Ischemiamedbookonline
 
Staging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladderStaging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladderAtulGupta369
 

Similaire à Evaluation of malignant ascites #176 (20)

Palliative treatment of malignant ascites #177
Palliative treatment of malignant ascites #177Palliative treatment of malignant ascites #177
Palliative treatment of malignant ascites #177
 
Malignant ascites dr. varun
Malignant ascites dr. varunMalignant ascites dr. varun
Malignant ascites dr. varun
 
Carcinoma rectum.pptx
Carcinoma rectum.pptxCarcinoma rectum.pptx
Carcinoma rectum.pptx
 
Austin Journal of Clinical Case Reports
Austin Journal of Clinical Case ReportsAustin Journal of Clinical Case Reports
Austin Journal of Clinical Case Reports
 
Premalignant conditions in Breast.pptx
Premalignant conditions in Breast.pptxPremalignant conditions in Breast.pptx
Premalignant conditions in Breast.pptx
 
Advances in the management of pancreatic cancer
Advances in the management of pancreatic cancerAdvances in the management of pancreatic cancer
Advances in the management of pancreatic cancer
 
Recent
RecentRecent
Recent
 
Recent
RecentRecent
Recent
 
Staging and investigation of hepatobillary ca
Staging and investigation of hepatobillary caStaging and investigation of hepatobillary ca
Staging and investigation of hepatobillary ca
 
Genetics
GeneticsGenetics
Genetics
 
Grish hcc presentation
Grish hcc presentationGrish hcc presentation
Grish hcc presentation
 
Gastroenterology-Part A.pptx
Gastroenterology-Part A.pptxGastroenterology-Part A.pptx
Gastroenterology-Part A.pptx
 
Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
 
Non-Alcoholic Tumor Disease
Non-Alcoholic Tumor DiseaseNon-Alcoholic Tumor Disease
Non-Alcoholic Tumor Disease
 
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Can...
 
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009
Acs0509 Tumors Of The Pancreas, Biliary Tract, And Liver 2009
 
Dr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with backgroundDr.yasar ahmed hcc with background
Dr.yasar ahmed hcc with background
 
Colo rectal cancer management
Colo rectal cancer managementColo rectal cancer management
Colo rectal cancer management
 
Acs0604 Acute Mesenteric Ischemia
Acs0604 Acute Mesenteric IschemiaAcs0604 Acute Mesenteric Ischemia
Acs0604 Acute Mesenteric Ischemia
 
Staging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladderStaging and investigation of ca kidney and bladder
Staging and investigation of ca kidney and bladder
 

Plus de Clinica de imagenes

Cuidados en la radioterapia interna
Cuidados en la radioterapia internaCuidados en la radioterapia interna
Cuidados en la radioterapia internaClinica de imagenes
 
Cuidados en la radioterapia externa
Cuidados en la radioterapia  externaCuidados en la radioterapia  externa
Cuidados en la radioterapia externaClinica de imagenes
 
Capacitacion nutricional corregida[1]
Capacitacion nutricional corregida[1]Capacitacion nutricional corregida[1]
Capacitacion nutricional corregida[1]Clinica de imagenes
 
Vendajes Pacientes Oncologicos - Lic Graciela Paez
Vendajes Pacientes Oncologicos - Lic Graciela PaezVendajes Pacientes Oncologicos - Lic Graciela Paez
Vendajes Pacientes Oncologicos - Lic Graciela PaezClinica de imagenes
 
Repaso de fisiología de la piel
Repaso de fisiología de la pielRepaso de fisiología de la piel
Repaso de fisiología de la pielClinica de imagenes
 
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp Clinica de imagenes
 
Carcinomas de cuello uterino y endometrio
Carcinomas  de cuello uterino y endometrioCarcinomas  de cuello uterino y endometrio
Carcinomas de cuello uterino y endometrioClinica de imagenes
 
Prevencion del cancer(bien hecho)
Prevencion del cancer(bien hecho)Prevencion del cancer(bien hecho)
Prevencion del cancer(bien hecho)Clinica de imagenes
 

Plus de Clinica de imagenes (20)

Cco egfr toxicities_2012_slides
Cco egfr toxicities_2012_slidesCco egfr toxicities_2012_slides
Cco egfr toxicities_2012_slides
 
Nutricion oncologicos[1]
Nutricion oncologicos[1]Nutricion oncologicos[1]
Nutricion oncologicos[1]
 
Cuidados en la radioterapia interna
Cuidados en la radioterapia internaCuidados en la radioterapia interna
Cuidados en la radioterapia interna
 
Cuidados en la radioterapia externa
Cuidados en la radioterapia  externaCuidados en la radioterapia  externa
Cuidados en la radioterapia externa
 
Capacitacion nutricional corregida[1]
Capacitacion nutricional corregida[1]Capacitacion nutricional corregida[1]
Capacitacion nutricional corregida[1]
 
Radioterapia seminario 2011
Radioterapia seminario 2011Radioterapia seminario 2011
Radioterapia seminario 2011
 
Vendajes Pacientes Oncologicos - Lic Graciela Paez
Vendajes Pacientes Oncologicos - Lic Graciela PaezVendajes Pacientes Oncologicos - Lic Graciela Paez
Vendajes Pacientes Oncologicos - Lic Graciela Paez
 
Repaso de fisiología de la piel
Repaso de fisiología de la pielRepaso de fisiología de la piel
Repaso de fisiología de la piel
 
Patologia mamaria enfermeria
Patologia mamaria enfermeriaPatologia mamaria enfermeria
Patologia mamaria enfermeria
 
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp
Mellanomaa Maligno, Cancer piel no Melanoma JMPJmp
 
Emergencias oncologicas
Emergencias oncologicasEmergencias oncologicas
Emergencias oncologicas
 
Emergencias oncologicas jmp
Emergencias oncologicas jmpEmergencias oncologicas jmp
Emergencias oncologicas jmp
 
Carcinomas de cuello uterino y endometrio
Carcinomas  de cuello uterino y endometrioCarcinomas  de cuello uterino y endometrio
Carcinomas de cuello uterino y endometrio
 
Ca de piel
Ca de pielCa de piel
Ca de piel
 
Quinmioterapia
QuinmioterapiaQuinmioterapia
Quinmioterapia
 
Prevencion del cancer(bien hecho)
Prevencion del cancer(bien hecho)Prevencion del cancer(bien hecho)
Prevencion del cancer(bien hecho)
 
Onco enf 10
Onco enf 10Onco enf 10
Onco enf 10
 
Manejo de cateteres
Manejo de cateteresManejo de cateteres
Manejo de cateteres
 
Extravasaciones
ExtravasacionesExtravasaciones
Extravasaciones
 
Estadísticas de cánc
Estadísticas de cáncEstadísticas de cánc
Estadísticas de cánc
 

Evaluation of malignant ascites #176

  • 1. JOURNAL OF PALLIATIVE MEDICINE Volume 13, Number 8, 2010 Fast Facts and Concepts ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2010.9800 Evaluation of Malignant Ascites #176 Karen LeBlanc and Robert M. Arnold, M.D. Background draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, M alignant ascites is the accumulation of abdominal fluid due to the direct effects of cancer. This Fast Fact reviews the causes and diagnosis of malignant ascites. Fast constrictive pericarditis, nephrotic syndrome, and peritoneal infections. Depending on the clinical presentation and expected sur- Fact #177 will review its treatment. vival, a diagnostic evaluation is usually indicated, as it will affect both prognosis and treatment approach. Key tests in- Pathophysiology clude the serum albumin and protein level and a simulta- neous diagnostic paracentesis, checking ascitic fluid white The pathophysiology of malignant ascites is incompletely blood cell count, albumin, protein, and cytology. understood. Contributing mechanisms include tumor-related obstruction of lymphatic drainage, increased vascular perme- Classification ability, over-activation of the renin-angiotensin-aldosterone system, neoplastic fluid production, and production of me- The old classification of exudative versus transudative as- talloproteinases that degrade the extracellular matrix. Portal cites has been updated using the serum-ascites albumin gra- venous compression can also occur from metastatic invasion of dient (SAAG). the liver, leading to peritoneal fluid accumulation. SAAG = (the serum albumin concentration) – (ascitic fluid albumin concentration) Natural History A SAAG 1.1 g/dl indicates ascites due to, at least in part, The most common cancers associated with ascites are ad- increased portal pressures, with an accuracy of 97%. This is enocarcinomas of the ovary, breast, colon, stomach, and most commonly seen in patients with cirrhosis, hepatic con- pancreas. Median survival after diagnosis of malignant ascites gestion, CHF, or portal vein thrombosis. is in the range of 1–4 months; survival is apt to be longer for A SAAG 1.1 g/dl indicates no portal hypertension, with ovarian and breast cancers if systemic anti-cancer treatments an accuracy of 97%; most commonly seen in peritoneal carci- are available. nomatosis, an infectious process of the peritoneum, nephrotic syndrome, or malnutrition/hypoalbuminemia. Presentation and Diagnostics Cytological evaluation is approximately 97% sensitive in Symptoms include abdominal distension, nausea, vomit- cases of peritoneal carcinomatosis, but is not helpful in the ing, early satiety, dyspnea, lower extremity edema, weight detection of other types of malignant ascites due to massive gain, and reduced mobility. Physical exam findings may in- hepatic metastasis or malignant obstruction of lymph vessels. clude abdominal distention, bulging flanks, shifting dullness, and a fluid wave. Plain abdominal x-rays are not specific, but References may show a hazy or a ‘‘ground glass’’ appearance. Ultrasound 1. Thomas J, von Gunten CF: Diagnosis and management of or CT scanning can confirm the presence of ascites and ascites. In Berger AM, Von Roenn J, Schuster J, eds. Principles demonstrate if the fluid is loculated in discrete areas of the and Practice of Palliative Care and Supportive Oncology, 3rd ed. peritoneal cavity. Philadelphia, PA: Lippincott, Williams Wilkins; 2006. There are many potential causes of ascites in the cancer 2. Adam RA, Adam YG: Malignant ascites: Past, present, and patient: peritoneal carcinomatosis, malignant obstruction of future. J Am Coll Surg 2004;198:999–1011. Fast Facts and Concepts are edited by Drew A Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For more information, write to: drosiell@mcw.edu. More information, as well as the complete set of Fast Facts, are available at EPERC: www.eperc.mcw.edu. Version History: Current version re-copy-edited in May 2009. Copyright/Referencing Information: Users are free to download and distribute Fast Facts for educational purposes only. LeBlanc K, Arnold RA. Evaluation of Malignant Ascites. Fast Facts and Concepts. March 2007; 176. Available at: www.eperc.mcw.edu/fastfact/ ff_176.htm. Disclaimer: Fast Facts and Concepts provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used. 1027
  • 2. 1028 FAST FACTS AND CONCEPTS 3. Spratt JS, Edwards M, Kubota T, et al: Peritoneal carcino- Address correspondence to: matosis: Anatomy, physiology, diagnosis, management. Curr Robert M. Arnold, M.D. Probl Cancer 1986;10:553–584. Division of Internal Medicine 4. Becker G, Galandi D, Blum HE: Malignant ascites: Systematic University of Pittsburgh review and guideline for treatment. Eur J Cancer 2006; 42:589–597. 200 N. Lothrop Street 5. Aslam N, Marino CR. Malignant ascites: New concepts in Pittsburgh, PA 15213 pathophysiology, diagnosis, and management. Arch Intern Med 2001; 161:2733–2737. E-mail: rabob@pitt.edu DOI: 10.1089/jpm.2010.9799 Palliative Treatment of Malignant Ascites #177 Karen LeBlanc and Robert M. Arnold, M.D. Background extended duration (peritonitis, accidental removal, leakage, occlusion). T he natural history, presenting signs/symptoms, and diagnostic approach to the patient with malignant ascites are discussed in Fast Fact #176; readers are encouraged b. Tunneled catheter: A catheter that prevents infection by promoting scarring around an antibiotic-impregnated Dacron cuff in subcutaneous tissue. Used convention- to read this Fast Fact to review the important role of deter- ally for peritoneal dialysis, it is placed with ultrasound mining the serum-ascites albumin gradient (SAAG) as a diag- or fluoroscopic guidance and has lower risks of infec- nostic and treatment aid. This Fast Fact will review treatment tion and leakage than the pigtail catheter. Complica- approaches. tions are reduced by daily drainage for the first 2 weeks of cuff healing. The Pleurx catheter is FDA approved 1. Diuretics for malignant ascites, and features a one-way rubber valve to prevent leaks between draining sessions. Malignant ascites (SAAG 1.1) generally does not re- Tunneled catheters are used in patients with a life ex- spond to diuretic treatment, although no randomized trials pectancy of at least 1 month. have been completed. Patients with evidence of portal hypertension (SAAG 1.1) are more likely to respond to diuretics. 4. Vascular Shunts 2. Paracentesis a. Peritovenous shunt (PVS) systems are designed to channel peritoneal fluid and proteins in benign as- Paracentesis can provide immediate relief of symptoms cites back into the circulation via the superior vena in up to 90% of patients. Drainage of uncomplicated large- cava. PVS has not been shown to have clinically volume ascites (4–6 L/session) can be done safely and quickly significant risk of disseminating tumor cells in in the outpatient setting—including the home—or at the malignant ascites. A PVS is placed by interventional hospital bedside; ultrasound guidance is necessary only when radiology under conscious sedation, and patients there is loculated fluid. typically require 24 hours of monitoring with a central venous line after the procedure. The best 3. Drainage catheters response to PVS (only about 50%) is in ovarian and breast cancers. PVS is recommended only in patients For patients who require frequent paracentesis, external with a life expectancy of 1 to 3 months. drainage catheters placed through the abdominal wall allow b. Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a frequent or continuous drainage of ascites fluid without re- shunt between the portal vein and hepatic vein, de- petitive needle insertions. Patients or caretakers may perform signed to reduce portal hypertension and improve the drainage, reducing visits to medical clinics. Several types sodium balance. Most patients with malignant ascites of catheters are available including: do not have portal hypertension although TIPS might a. Pigtail catheter: A simple, temporary all-purpose cath- be helpful in the occasional cancer with evidence of eter; prone to complications when used over an increased portal pressures (SAAG 1.1).